Hazards and Benefits of Postnatal Steroids. David J. Burchfield, MD Professor and Chief, Neonatology University of Florida
|
|
- Blaze Carpenter
- 6 years ago
- Views:
Transcription
1 Hazards and Benefits of Postnatal Steroids David J. Burchfield, MD Professor and Chief, Neonatology University of Florida
2 Disclosures I have no financial affiliations or relationships to disclose. I will be discussing the off-label use of dexamethasone.
3 Objectives Become familiar with the history of steroid use in neonatal chronic lung disease Understand the benefits of steroid use for CLD Understand the risks of steroid use for CLD Leave with an understanding of a practical way to use post-natal steroids
4 Old BPD
5 Lung Pathology in BPD Normal BPD
6 Pathophysiology of BPD
7 Steroids to Prevent/Treat BPD Lancet June 18,1983:
8 Mammel infants On ventilator x 4 weeks Treated with diuretics, methylxanthines, bronchodilators, fluid restriction, nutritional supplementation, and ligation of the patent ductus arteriosus Cross-over design Each infant their own control Dex or placebo x 3 days Mammel et al:lancet Jun 18;1(8338):
9 Mammel 1983 Lancet June 18,1983:
10 Mammel 1983 Lancet June 18,1983:
11 Mammel 1983 Lancet June 18,1983:
12 Mammel 1983 The long term effects of dexamethasone treatment in neonates are not clear Infection Growth retardation Adrenal suppression Possibly neurodevelopmental compromise Lancet June 18,1983:
13 Steroids to Prevent/Treat BPD
14 Avery Study infants > 2 weeks old No wean x 5 days 42 day course of dex vs placebo
15
16 Avery Study 1985
17 Avery 1985
18 Cummings 1989 N Engl J Med 1989: 320(23):
19 Cummings groups: Dex x 42 d Dex x 18 d Placebo > 2 weeks Rate > 15 FiO2 > 0.3 No wean x 72 h N Engl J Med 1989: 320(23):
20 Cummings 1989 N Engl J Med 1989: 320(23):
21 Cummings 1989 N Engl J Med 1989: 320(23):
22 Summary from 1980 s Dexamethasone 0.5 mg/kg BID was initial starting dose On ventilator at least 14 days with no weaning occurring prior to randomization Improvement in respiratory physiology No major impact on mortality
23 Early Steroids Yeh patients randomized <12 hr old Dex PEDIATRICS Vol. 100 No. 4 October 1997, p. e3
24 Yeh 1997 TABLE 3 Mortality and CLD Morbidity Placebo No. of Infants Mortality CLD Morbidity <1000 g (38.5%) 14 (53.8%) g (28.9%) 18 (30.5%) >1500 g (26.7%) 8 (18%) Dexamethasone <1000 g (44.8%) 7 (24.1%)* g (31.8%) 9 (14%)* >1500 g (27.0%) 5 (14%) * P <.05 (dexamethasone vs placebo). PEDIATRICS Vol. 100 No. 4 October 1997, p. e3
25 Yeh 1997 Early postnatal dexamethasone therapy, given within 12 hours after birth for 1 week and tapering over 3 weeks, Significantly reduced the incidence of CLD Permitted earlier weaning from mechanical ventilation. Transient side effects: Increase in blood glucose, BUN, and serum potassium; Increase in blood pressure and cardiac hypertrophy; Increase in parathyroid hormone and in urinary excretion of phosphate; Increase in degree of weight loss. Higher incidence of infection. No effect on ROP, IVH, head circumference, height, or bone growth. With significant, although transient, side effects of the early postnatal use of steroid and the lack of overall improvement in outcome and mortality, our recommendation regarding its routine use remains cautious until the result of a long-term follow-up study is available.
26 Discrepancies in Clinical Trials Age at drug administration Dose of drug Degree of illness Cross-over
27 Cochrane Systematic Review Evaluated the evidence at 3 ages of administration Early--< 96 hours of life 21 randomized control trials, 3072 patients Moderately early 7-14 days 7 studies, 660 total patients Late 3 weeks of life 9 trials, 562 patients Total 37 trials and 4,294 patients Halliday, HL; Ehrenkranz, RA; Doyle, LW The Cochrane Database of Systematic Reviews, Volume (4), 2006
28 Cochrane Early
29 Cochrane 2008 Early CP
30 CP--Early Number needed to harm=14
31 Conclusions of Cochrane Review Benefits Earlier extubation Decreased risks of CLD Need to treat 10 babies to prevent one case Decreased risk of death or CLD at 28 days and 36 weeks Risks Gastrointestinal bleeding, intestinal perforation, hyperglycemia, and hypertension, Long-term risks of abnormal neurological exam and cerebral palsy. Halliday, HL; Ehrenkranz, RA; Doyle, LW The Cochrane Database of Systematic Reviews, Volume (4), 2006
32 Halliday, HL; Ehrenkranz, RA; Doyle, LW The Cochrane Database of Systematic Reviews, Volume (4), 2006 Conclusions of Cochrane Review It appears appropriate to curtail early corticosteroid treatment for prevention of chronic lung disease. however, 448 of the 925 control infants (48%) received post-natal steroids off study Effect on survival of these control infants?
33 Moderately Early (7-14 days) 7 studies 660 total patients Halliday, HL; Ehrenkranz, RA; Doyle, LW : The Cochrane Library, Volume (4).2006
34 Moderately Early--Mortality Halliday, HL; Ehrenkranz, RA; Doyle, LW : The Cochrane Library, Volume (4).2006
35 Moderately Early CLD Halliday, HL; Ehrenkranz, RA; Doyle, LW : The Cochrane Library, Volume (4).2006
36 Moderately Early--CP Halliday, HL; Ehrenkranz, RA; Doyle, LW : The Cochrane Library, Volume (4).2006
37 Conclusions (7-14 Days) Benefits Reductions in failure to extubate Reduction in CLD Reduction in mortality, Risks Limited evidence concerning long term effects is provided by the trials included in this review. Halliday, HL; Ehrenkranz, RA; Doyle, LW : The Cochrane Library, Volume (4).2006
38 Conclusions (7-14 Days) Given the risks of short-term and potentially long-term adverse effects versus the shortterm benefits, it appears appropriate to reserve moderately early corticosteroid treatment to infants who cannot be weaned from mechanical ventilation and to minimize the dose and duration of any course of therapy. Halliday, HL; Ehrenkranz, RA; Doyle, LW : The Cochrane Library, Volume (4).2006
39 7-14 Days My Observations Mortality reduced at 28 days with NNT of 9 CLD decreased at 36 weeks adjusted, with NNT of 4 Mortality or CLD decreased at 36 weeks with NNT <4 No data on cross-over
40 Late Postnatal Steroids 3 weeks 9 trials 562 patients Halliday, HL; Ehrenkranz, RA; Doyle, LW The Cochrane Database of Systematic Reviews Volume (4), 2006
41 > 3 Weeks--Mortality Halliday, HL; Ehrenkranz, RA; Doyle, LW The Cochrane Database of Systematic Reviews Volume (4), 2006
42 > 3weeks CLD Note only one study Halliday, HL; Ehrenkranz, RA; Doyle, LW The Cochrane Database of Systematic Reviews Volume (4), 2006
43 Failure to extubate in 1 Week Halliday, HL; Ehrenkranz, RA; Doyle, LW The Cochrane Database of Systematic Reviews Volume (4), 2006
44 MDI and PDI 3 Weeks Halliday, HL; Ehrenkranz, RA; Doyle, LW The Cochrane Database of Systematic Reviews Volume (4), 2006
45 Cerebral Palsy Halliday, HL; Ehrenkranz, RA; Doyle, LW The Cochrane Database of Systematic Reviews Volume (4), 2006
46 Conclusions 3 weeks The benefits of late corticosteroid therapy may not outweigh actual or potential adverse effects. 78 of 192 control infants received steroids (40%)
47 Long Term Neurological Effects of Postnatal Steroids Barrington Study 8 randomized controlled trials with long term follow-up data Together, randomized 1052 infants 292 of whom are known to have died the relative risk of death is not statistically significant in any of the studies Barrington KJ: BMC Pediatr. 2001; 1: 1
48 Long Term Neurological Effects of Postnatal Steroids Barrington Study Survival L E E E M,L M E L Barrington KJ: BMC Pediatr. 2001; 1: 1
49 Long Term Neurological Effects of Postnatal Steroids Barrington Study Neurological Impairment Barrington KJ: BMC Pediatr. 2001; 1: 1
50 Conclusion of Barrington Study The number of premature infants who need to be treated to have one more infant with cerebral palsy (number needed to harm, NNH) is 7; To have one more infant with neurodevelopmental impairment the NNH is 11. No survival benefits
51 AAP Committee on Fetus and Newborn (2002) The short-term pulmonary benefits of systemic dexamethasone do not appear to confer long-term benefits. Survival does not improve after dexamethasone administration. Furthermore, data indicating an increased incidence of neurodevelopmental delay and cerebral palsy raise serious concerns about adverse long-term outcomes Pediatrics Feb;109(2):330-8
52 Are we throwing out the baby with the bath water?? From early and late trials, 47% of the control infants still received rescue therapy with steroids. Studies included trials with neonates who were not at high risk of dying
53 A, Moderately early trial meta-regression analysis of the percentage of Open Label Glucocorticoids in the placebo group and the effect on the mortality-at-hospital-discharge outcome. Onland W et al. Pediatrics 2010;126:e954-e by American Academy of Pediatrics
54 Not That Sick but almost showed survival benefit O Shea % of Dex-treated infants survived to 1 year adjusted age, compared with 74% of placebo recipients (P =.066) FIO2 at entry Steroid Control Jones 1995 Collaborative trial from 31 centers 66% on ventilator 23% had an FiO2 >60%
55 RD (%) for death or CP among all participants versus rate of CLD (%) in the control group. Doyle L W et al. Pediatrics 2005;115: by American Academy of Pediatrics
56
57 What does new study add? Only included studies after 1 st week of life Nineteen RCTs qualified for inclusion in this review These trials enrolled preterm infants who were oxygen- and/or ventilator-dependent beyond 7 days of age.
58 RESULTS
59 RESULTS
60 RESULTS
61 Summary of Benefits
62 Summary of Side Effects
63 Discussion Data on long-term neurosensory followup were available from 12 studies comprising 800 infants randomized. The significant increase in abnormal neurological examination in those randomized is of potential concern; tempered by the findings that cerebral palsy and major neurosensory disability, both overall and in survivors, were not significantly increased
64 Discussion Lower doses and shorter courses should be considered for these infants DART study, with a total dose of only 0.89 mg/kg over 10 days, was able to demonstrate acute benefits of extubation and reduced respiratory support. Further studies of low-dose systemic corticosteroids initiated beyond the first week of life in infants at high risk of developing BPD are also warranted
65 DART Trial: Kaplan-Meier survival curve for proportion failing to extubate over the 10 days of treatment. Doyle L W et al. Pediatrics 2006;117: by American Academy of Pediatrics
66 Policy Statement Postnatal Corticosteroids to Prevent or Treat Bronchopulmonary Dysplasia High-dose dexamethasone (0.5 mg/kg per day) does not seem to confer additional therapeutic benefit over lower doses and is not recommended. Evidence is insufficient to make a recommendation regarding other glucocorticoid doses and preparations. The clinician must use clinical judgment when attempting to balance the potential adverse effects of glucocorticoid treatment with those of bronchopulmonary dysplasia Pediatrics 2010;126:
67 Current Usage of Postnatal Steroids
68 Summary---Patient selection is key 1) Is the baby really sick? Develop unit-based guidelines for FiO2 and ventilator settings 2) Have you given TIME a chance? Probably should not consider until >1 week of age 3) Is the baby medically stable to receive steroids? No indomethacin, no acute infections 4) Don t overdo it dose and duration
Noah Hillman M.D. IPOKRaTES Conference Guadalajaira, Mexico August 23, 2018
Postnatal Steroids Use for Bronchopulmonary Dysplasia in 2018 + = Noah Hillman M.D. IPOKRaTES Conference Guadalajaira, Mexico August 23, 2018 AAP Policy Statement - 2002 This statement is intended for
More informationKristi Watterberg, MD University of New Mexico
Kristi Watterberg, MD University of New Mexico Dr. Watterberg has no financial or other conflicts of interest to disclose She will be discussing studies of glucocorticoids in preterm infants History how
More informationPostnatal Steroid (PNS) Administration: Rationale
Postnatal Steroid (PNS) Administration: Rationale Background: Postnatal steroid use has been subjected to intense scrutiny in recent years, the subject of several metaanalyses and most recently been the
More informationPostnatal Corticosteroids for the Prevention and Treatment of Chronic Lung Disease in Preterm Infants
Postnatal Corticosteroids for the Prevention and Treatment of Chronic Lung Disease in Preterm Infants Clinical trial evidence for the effectiveness of corticosteroids in the prevention of CLD is strong
More informationEarly (< 8 days) postnatal corticosteroids for preventing chronic lung disease in preterm infants (Review)
Early (< 8 days) postnatal corticosteroids for preventing chronic lung disease in preterm infants (Review) Halliday HL, Ehrenkranz RA, Doyle LW This is a reprint of a Cochrane review, prepared and maintained
More informationPatent Ductus Arteriosus: Philosophy or Pathology?
Patent Ductus Arteriosus: Philosophy or Pathology? Disclosure Ray Sato, MD is a speaker for Prolacta Biosciences, Inc. This presentation will discuss off-label uses of acetaminophen and ibuprofen. RAY
More informationPlanning Committee: Jeffery D. Horbar, MD, Madge E. Buus-Frank, RN, MS, APRN-BC, FAAN, Roger F. Soll, MD
Title of Program: What has Cochrane Neonatal Done For Babies? Speakers/Moderators: Roger F. Soll, MD Planning Committee: Jeffery D. Horbar, MD, Madge E. Buus-Frank, RN, MS, APRN-BC, FAAN, Roger F. Soll,
More informationPATENT DUCTUS ARTERIOSUS IN THE PRETERM INFANT EVIDENCE FOR & AGAINST TREATMENT
PATENT DUCTUS ARTERIOSUS IN THE PRETERM INFANT EVIDENCE FOR & AGAINST TREATMENT Dr. Youssef Abou Zanouna, FRCPI, FACC Consultant Pediatric Cardiologist King Fahd Military Medical Complex Dhahran Introduction
More informationThe Basics. Editorial Team. Editorial Team 9/28/2017
Title of Program: What has Cochrane Neonatal Done For Babies? Speakers/Moderators: Roger F. Soll, MD Planning Committee: Jeffery D. Horbar, MD, Madge E. Buus-Frank, RN, MS, APRN-BC, FAAN, Roger F. Soll,
More informationUpdate on mangement of patent ductus arteriosus in preterm infants. Dr. Trinh Thi Thu Ha
Update on mangement of patent ductus arteriosus in preterm infants Dr. Trinh Thi Thu Ha Outline 1. Overview of PDA 2. Timing of screening PDA? 3. When to treat PDA? Timing of ductal closure Prenatal
More informationLate(œ 7 days) systemic postnatal corticosteroids for prevention of bronchopulmonary dysplasia in preterm infants(review)
Cochrane Database of Systematic Reviews Late(œ 7 days) systemic postnatal corticosteroids for prevention of bronchopulmonary dysplasia in preterm infants (Review) Doyle LW, Cheong JL, Ehrenkranz RA, Halliday
More informationShort-Term Outcome Of Different Treatment Modalities Of Patent Ductus Arteriosus In Preterm Infants. Five Years Experiences In Qatar
ISPUB.COM The Internet Journal of Cardiovascular Research Volume 7 Number 2 Short-Term Outcome Of Different Treatment Modalities Of Patent Ductus Arteriosus In Preterm Infants. Five Years Experiences In
More informationPEDIATRIC NEWBORN MEDICINE CLINICAL PRACTICE GUIDELINES Pharmacologic Strategies for the Prevention of Bronchopulmonary Dysplasia
PEDIATRIC NEWBORN MEDICINE CLINICAL PRACTICE GUIDELINES Pharmacologic Strategies for the Prevention of Bronchopulmonary Dysplasia Clinical Practice Guideline: Pharmacologic Strategies for the Prevention
More informationPEDIATRIC PHARMACOTHERAPY
PEDIATRIC PHARMACOTHERAPY Volume 22 Number 12 December 2016 A The Role of Hydrocortisone in the Management of Bronchopulmonary Dysplasia Emily Monds, PharmD lthough the clinical landscape of bronchopulmonary
More informationClinical Study Pulmonary Effects of Neonatal Hydrocortisone Treatment in Ventilator-Dependent Preterm Infants
International Pediatrics Volume 2011, Article ID 783893, 7 pages doi:10.1155/2011/783893 Clinical Study Pulmonary Effects of Neonatal Hydrocortisone Treatment in Ventilator-Dependent Preterm Infants Sandra
More informationMcMASTER NICU INHALED STEROIDS FOR EVOLVING BPD (GA < 29 WEEKS)
McMASTER NICU INHALED STEROIDS FOR EVOLVING BPD (GA < 29 WEEKS) Developed by: Amit Mukerji, Samira Samiee-Zafarghandy, Jennifer Twiss, Ereny Bassilious, Elizabeth Vo, Shari Gray, Salhab el Helou on behalf
More informationSatellite Symposium. Sponsored by
Satellite Symposium Sponsored by Management of fluids and electrolytes in the preterm infant in the first week of life Pam Cairns St Michaels Hospital Bristol Healthy, term, breast fed babies Limited intake
More informationEarly postnatal dexamethasone administration
Controlled Trial of Early Dexamethasone Treatment for the Prevention of Chronic Lung Disease in Preterm Infants: A 3-Year Follow-up Costantino Romagnoli, MD*; Enrico Zecca, MD*; Rita Luciano, MD*; Giulia
More informationReview Article Postnatal Corticosteroids for Prevention and Treatment of Chronic Lung Disease in the Preterm Newborn
International Journal of Pediatrics Volume 2012, Article ID 315642, 12 pages doi:10.1155/2012/315642 Review Article Postnatal Corticosteroids for Prevention and Treatment of Chronic Lung Disease in the
More informationROLE OF EARLY POSTNATAL DEXAMETHASONE IN RESPIRATORY DISTRESS SYNDROME
INDIAN PEDIATRICS VOLUME 35-FEBRUAKY 1998 ROLE OF EARLY POSTNATAL DEXAMETHASONE IN RESPIRATORY DISTRESS SYNDROME Kanya Mukhopadhyay, Praveen Kumar and Anil Narang From the Division of Neonatology, Department
More informationAMERICAN ACADEMY OF PEDIATRICS CANADIAN PAEDIATRIC SOCIETY. Postnatal Corticosteroids to Treat or Prevent Chronic Lung Disease in Preterm Infants
AMERICAN ACADEMY OF PEDIATRICS Committee on Fetus and Newborn CANADIAN PAEDIATRIC SOCIETY Fetus and Newborn Committee Postnatal Corticosteroids to Treat or Prevent Chronic Lung Disease in Preterm Infants
More informationPostnatal corticosteroids to treat or prevent chronic lung disease in preterm infants.
Complete Summary GUIDELINE TITLE Postnatal corticosteroids to treat or prevent chronic lung disease in preterm infants. BIBLIOGRAPHIC SOURCE(S) Postnatal corticosteroids to treat or prevent chronic lung
More informationOriginal Policy Date
MP 8.01.17 Inhaled Nitric Oxide Medical Policy Section Therapy Issue 12/2013 Original Policy Date 12/2013 Last Review Status/Date Reviewed with literature search/12/2013 Return to Medical Policy Index
More informationResearch Roundtable Summary
Research Roundtable Summary 10 TENTH in a Series of Seminars on MCHB-funded Research Projects Early Cortisol Deficiency and Bronchopulmonary Dysplasia October 18, 1995 Parklawn Building Potomac Conference
More informationBenefits of Caffeine Citrate: Neurodevelopmental Outcomes of ELBW Infants
St. Catherine University SOPHIA Master of Arts in Nursing Theses Nursing 12-2011 Benefits of Caffeine Citrate: Neurodevelopmental Outcomes of ELBW Infants Teri Johnson St. Catherine University Follow this
More informationObjectives. Apnea Definition and Pitfalls. Pathophysiology of Apnea. Apnea of Prematurity and hypoxemia episodes 5/18/2015
Apnea of Prematurity and hypoxemia episodes Deepak Jain MD Care of Sick Newborn Conference May 2015 Objectives Differentiating between apnea and hypoxemia episodes. Pathophysiology Diagnosis of apnea and
More informationAn Overview of Bronchopulmonary Dysplasia and Chronic Lung Disease in Infancy
An Overview of Bronchopulmonary Dysplasia and Chronic Lung Disease in Infancy Housekeeping: I have no financial disclosures Learning objectives: Develop an understanding of bronchopulmonary dysplasia (BPD)
More informationPDA: As the Pendulum Swings. Cathy Hammerman Shaare Zedek Medical Center & Hebrew University Faculty of Medicine, Jerusalem, Israel
PDA: As the Pendulum Swings Cathy Hammerman Shaare Zedek Medical Center & Hebrew University Faculty of Medicine, Jerusalem, Israel Six Blind Neonatologists Approach PDA It s not physiologic - all must
More informationPAEDIATRIC RESPIRATORY FAILURE. Tang Swee Fong Department of Paediatrics University Kebangsaan Malaysia Medical Centre
PAEDIATRIC RESPIRATORY FAILURE Tang Swee Fong Department of Paediatrics University Kebangsaan Malaysia Medical Centre Outline of lecture Bronchiolitis Bronchopulmonary dysplasia Asthma ARDS Bronchiolitis
More information1
1 2 3 RIFAI 5 6 Dublin cohort, retrospective review. Milrinone was commenced at an initial dose of 0.50 μg/kg/minute up to 0.75 μg/kg/minute and was continued depending on clinical response. No loading
More informationChronic Lung Disease Of Prematurity. Dr Jo Harrison
Chronic Lung Disease Of Prematurity Dr Jo Harrison 9.9.14 Chronic Neonatal Lung Disease Bronchopulmonary dysplasia (BPD) first described in 1967 by Northway Defined as O 2 dependence at 28 days post birth
More informationUSE OF INHALED NITRIC OXIDE IN THE NICU East Bay Newborn Specialists Guideline Prepared by P Joe, G Dudell, A D Harlingue Revised 7/9/2014
USE OF INHALED NITRIC OXIDE IN THE NICU East Bay Newborn Specialists Guideline Prepared by P Joe, G Dudell, A D Harlingue Revised 7/9/2014 ino for Late Preterm and Term Infants with Severe PPHN Background:
More informationThe New England Journal of Medicine A MULTICENTER TRIAL OF TWO DEXAMETHASONE REGIMENS IN VENTILATOR-DEPENDENT PREMATURE INFANTS
A MULTICENTER TRIAL OF TWO REGIMENS IN VENTILATOR-DEPENDENT PREMATURE INFANTS LU-ANN PAPILE, M.D., JON E. TYSON, M.D., BARBARA J. STOLL, M.D., LINDA L. WRIGHT, M.D., EDWARD F. DONOVAN, M.D., CHARLES R.
More informationBRONCHOPULMONARY DYSPLASIA
BRONCHOPULMONARY DYSPLASIA CHRONIC NEONATAL LUNG DISEASE (CLD) 2 2 nd BERLIN NEONATOLOGY SUMMER SCHOOL September 2014 3 Mt. Scopus 4 Ein Kerem 5 BRONCHOPULMONARY DYSPLASIA 1960: Ventilation of Neonates
More informationRescue Therapies in Neonatology. February 2014 Bill Walsh Monroe Carell Jr Children s Vanderbilt
Rescue Therapies in Neonatology February 2014 Bill Walsh Monroe Carell Jr Children s Vanderbilt Off Label Use-Disclaimer All discussion in this talk concerns off-label use of nitric oxide, steroids, and
More informationTEXAS CHILDREN S HOSPITAL EVIDENCE-BASED OUTCOMES CENTER Respiratory Management of the Preterm Infant Evidence Summary
TEXAS CHILDREN S HOSPITAL EVIDENCE-BASED OUTCOMES CENTER Respiratory Management of the Preterm Infant Evidence Summary DATE: April 2016 Critically Analyze the Evidence The GRADE criteria were used to evaluate
More informationResearch Article Timing of Caffeine Therapy and Neonatal Outcomes in Preterm Infants: A Retrospective Study
International Pediatrics Volume 2016, Article ID 9478204, 6 pages http://dx.doi.org/10.1155/2016/9478204 Research Article Timing of Caffeine Therapy and Neonatal Outcomes in Preterm Infants: A Retrospective
More informationexposure/intervention
Kathleen A. Kennedy, MD, MPH University of Texas Medical School at Houston Medical School Most clinical research evaluates an association between exposure/intervention outcome. 1 Does the investigator
More informationDISCLOSURE FUNDING BRONCHOPULMONARY DYPLASIA (BPD) UCSF. Preventing BPD: Is Inhaled Nitric Oxide the Answer? March, 2009
Preventing BPD: Is Inhaled Nitric Oxide the Answer? March, 2009 Roberta A. Ballard Professor of Pediatrics UCSF DISCLOSURE INO THERAPEUTICS (IKARIA) has provided: * Inhaled Nitric Oxide (INOmax) * Delivery
More informationIs There a Treatment for BPD?
Is There a Treatment for BPD? Amir Kugelman, Pediatric Pulmonary Unit and Department of Neonatology Bnai Zion Medical Center, Rappaport Faculty of Medicine Haifa, Israel Conflict of Interest Our study
More informationRespiratory Management and Outcome of Preterm Infants
Respiratory Management and Outcome of Preterm Infants 6 th Annual Care Of The Sick Newborn Conference Shu Wu, MD. Department of Pediatrics Division of Neonatology University of Miami School of Medicine
More informationBest Practices in Bronchopulmonary
Best Practices in Bronchopulmonary Dysplasia a (BPD) Prevention e Matthew M. Laughon, MD, MPH Professor of Pediatrics The University of North Carolina at Chapel Hill I receive support from the U.S. government
More informationIbuprofen for the prevention of patent ductus arteriosus in preterm and/or low birth weight infants (Review)
Ibuprofen for the prevention of patent ductus arteriosus in preterm and/or low birth weight infants (Review) Ohlsson A, Shah SS This is a reprint of a Cochrane review, prepared and maintained by The Cochrane
More informationAn Update on Caffeine Therapy
An Update on Caffeine Therapy Emory University School of Medicine Atlanta, GA Wally Carlo, MD University of Alabama at Birmingham Department of Pediatrics Division of Neonatology wcarlo@peds.uab.edu Objectives
More informationA2b. PDA Management--A Reflection on the Evidence: Does it Help with Management? Session Summary. Session Objectives. References.
FANNP 23RD NATIONAL NNP SYMPOSIUM: CLINICAL UTE AND REVIEW A2b Management--A Reflection on the Evidence: Does it Help with Management? Alfonso Vargas, MD Neonatologist Pediatrix Medical Group, Tampa, FL
More informationSWISS SOCIETY OF NEONATOLOGY. Preterm infant with. pulmonary hypertension and hypopituitarism
SWISS SOCIETY OF NEONATOLOGY Preterm infant with pulmonary hypertension and hypopituitarism November 2007 2 Pilgrim S, Stocker M, Neonatal and Pediatric Intensiv Care Unit, Children s Hospital of Lucerne,
More informationIMPAIRED CEREBRAL CORTICAL GRAY MATTER GROWTH FOLLOWING TREATMENT WITH DEXAMETHASONE FOR NEONATAL CHRONIC LUNG DISEASE
IMPAIRED CEREBRAL CORTICAL GRAY MATTER GROWTH FOLLOWING TREATMENT WITH DEXAMETHASONE FOR NEONATAL CHRONIC LUNG DISEASE Brendan P. Murphy, MB BCh 1, Terrie E. Inder, MD 2,5, Petra S. Huppi, MD 3,5, Simon
More informationInfant Nutrition & Growth to Optimize Outcome Fauzia Shakeel, MD
Infant Nutrition & Growth to Optimize Outcome Fauzia Shakeel, MD Neonatologist All Children s Hospital / Johns Hopkins Medicine Affiliate Assistant Professor, University of South Florida September 2014
More informationFANNP 28TH NATIONAL NNP SYMPOSIUM: CLINICAL UPDATE AND REVIEW OCTOBER 17-21, 2017
Pulse Oximetry in the Delivery Room: Principles and Practice GS2 3 Jonathan P. Mintzer, MD, FAAP Assistant Professor of Pediatrics Stony Brook Children s Hospital, Division of Neonatal-Perinatal Medicine,
More informationSAMPLE. V.12.1 Special Report: Very Low Birthweight Neonates. I. Introduction
I. Introduction V.12.1 Special Report: Very Low Birthweight Neonates The delivery of a very low birth weight infant continues to present many challenges to families and health care providers in spite of
More informationBPD. Neonatal/Pediatric Cardiopulmonary Care. Disease. Bronchopulmonary Dysplasia. Baby Jane
1 Neonatal/Pediatric Cardiopulmonary Care Disease 2 Bronchopulmonary Dysplasia 3 is a 33-day-old prematurely born girl who weighs 1420 g. At birth, her estimated gestational age was 28 weeks. Her initial
More informationDiuretics: Increased risk of renal dysfunction. (7) See 17 for PATIENT COUNSELING INFORMATION. Revised: 10/2017 FULL PRESCRIBING INFORMATION: CONTENTS
HIGHLIGHTS OF PRESCRIBING INFORMATION These highlights do not include all the information needed to use NEOPROFEN safely and effectively. See full prescribing information for NEOPROFEN. NEOPROFEN (ibuprofen
More informationNEONATAL NEWS Here s Some More Good Poop
NEONATALNEWS Here ssomemoregoodpoop WINTEREDITION2010 THISNEWSLETTERISPUBLISHEDPERIODICALLYBYTHENEONATOLOGISTSOF ASSOCIATESINNEWBORNMEDICINETOCONVEYNEWANDUPDATEDPOLICIES ANDGUIDELINESANDPROVIDEGENERALEDUCATIONTONICUCARETAKERSAT
More informationSURFACTANT UPDATE. George Mandy, M.D. Nationwide Children s Hospital The Ohio State University
SURFACTANT UPDATE George Mandy, M.D. Nationwide Children s Hospital The Ohio State University Surfactant Update Objectives History Meta-analysis of surfactant therapy New synthetic surfactant Genetic disorders
More informationIs there any Benefit to Closing the Ductus Arteriosus?
Controversies in the Management of a Patent Ductus Arteriosus Is there any Benefit to Closing the Ductus Arteriosus? Richard A. Polin M.D. Morgan Stanley Children s Hospital Columbia University Galen 130-200
More informationRango de saturacion de oxigeno: Cual es la evidencia?
Rango de saturacion de oxigeno: Cual es la evidencia? Wally Carlo, M.D. University of Alabama at Birmingham Department of Pediatrics Division of Neonatology wcarlo@peds.uab.edu 1 2 Stevie Wonder 4 Objectives
More informationProphylactic Aminophylline for Prevention of Apnea at Higher-Risk Preterm Neonates
Iran Red Crescent Med J. 2014 August; 16(8): e12559. Published online 2014 August 5. DOI: 10.5812/ircmj.12559 Research Article Prophylactic Aminophylline for Prevention of Apnea at Higher-Risk Preterm
More informationBy: Armend Lokku Supervisor: Dr. Lucia Mirea. Maternal-Infant Care Research Center, Mount Sinai Hospital
By: Armend Lokku Supervisor: Dr. Lucia Mirea Maternal-Infant Care Research Center, Mount Sinai Hospital Background My practicum placement was at the Maternal-Infant Care Research Center (MiCare) at Mount
More informationPrematurity as a Risk Factor for ASD. Disclaimer
Prematurity as a Risk Factor for ASD Angela M. Montgomery, MD, MSEd Assistant Professor of Pediatrics (Neonatology) Director, Yale NICU GRAD Program Suzanne L. Macari, PhD Research Scientist, Child Study
More informationThe Patent Ductus Arteriosus (PDA) and the Preterm Baby. Tanya Hatfield, RNC-NIC, MSN Neonatal Outreach Educator
The Patent Ductus Arteriosus (PDA) and the Preterm Baby Tanya Hatfield, RNC-NIC, MSN Neonatal Outreach Educator Objectives Describe normal cardiac physiology and development Understand the unique physiologic
More informationCOMPARISON OF THE EFFICIENCY OF CAFFEINE VERSUS AMINOPHYLLINE FOR THE TREATMENT OF APNOEA OF PREMATURITY
CASE STUDIES COMPARISON OF THE EFFICIENCY OF CAFFEINE VERSUS AMINOPHYLLINE FOR THE TREATMENT OF APNOEA OF PREMATURITY Gabriela Ildiko Zonda 1, Andreea Avasiloaiei 1, Mihaela Moscalu 2, Maria Stamatin 1
More informationPrematurity: Optimizing Growth in the NICU for Later Metabolic Outcomes
Prematurity: Optimizing Growth in the NICU for Later Metabolic Outcomes Malki Miller MS, RD, CNSC Neonatal Dietitian, Maimonides Infants and Children s Hospital Adjunct Lecturer of Human and Pediatric,
More informationPolicy #: 440 Latest Review Date: May 2016
Name of Policy: Inhaled Nitric Oxide Policy #: 440 Latest Review Date: May 2016 Category: Therapy Policy Grade: B Background/Definitions: As a general rule, benefits are payable under Blue Cross and Blue
More informationAdjunct Therapies for Pediatric ARDS: Where are the Data?
Adjunct Therapies for Pediatric ARDS: Where are the Data? Alexandre T. Rotta, MD, FCCM Professor of Pediatrics, Linsalata Family Endowed Chair in Pediatric Critical Care and Emergency Medicine Rainbow
More informationName and title of the investigators responsible for conducting the research: Dr Anna Lavizzari, Dr Mariarosa Colnaghi
Protocol title: Heated, Humidified High-Flow Nasal Cannula vs Nasal CPAP for Respiratory Distress Syndrome of Prematurity. Protocol identifying number: Clinical Trials.gov NCT02570217 Name and title of
More informationDisclosures. Learning Objectives. Mechanical Ventilation of Infants with Severe BPD: An Interdisciplinary Approach 3/10/2017
Mechanical Ventilation of Infants with Severe BPD: An Interdisciplinary Approach Steven H. Abman, MD Professor, Department of Pediatrics Director, Pediatric Heart Lung Center University of Colorado School
More informationBack to the Future: Updated Guidelines for Evaluation and Management of Adrenal Insufficiency in the Critically Ill
Back to the Future: Updated Guidelines for Evaluation and Management of Adrenal Insufficiency in the Critically Ill Joe Palumbo PGY-2 Critical Care Pharmacy Resident Buffalo General Medical Center Disclosures
More informationLearning Objectives. At the conclusion of this module, participants should be better able to:
Learning Objectives At the conclusion of this module, participants should be better able to: Treat asymptomatic neonatal hypoglycemia with buccal dextrose gel Develop patient-specific approaches to intravenous
More informationOutcomes at School Age after Postnatal Dexamethasone Therapy for Lung Disease of Prematurity
The new england journal of medicine original article Outcomes at School Age after Postnatal Dexamethasone Therapy for Lung Disease of Prematurity Tsu F. Yeh, M.D., Yuh J. Lin, M.D., Hung C. Lin, M.D.,
More informationSTOP ROP The STOP-ROP Multicenter Study Group: Pediatrics 105:295, 2000 Progression to Threshold Conventional Sat 89-94% STOP ROP
Hrs TcPO2 > 80 nnhg (weeks 1 4) OXYGEN TARGETS: HOW GOOD ARE WE IN ACHIEVING THEM Oxygen Dependency GA wks Eduardo Bancalari MD University of Miami Miller School of Medicine Jackson Memorial Medical Center
More informationHyaline membrane disease. By : Dr. Ch Sarishma Peadiatric Pg
Hyaline membrane disease By : Dr. Ch Sarishma Peadiatric Pg Also called Respiratory distress syndrome. It occurs primarily in premature infants; its incidence is inversely related to gestational age and
More informationPediatric Cardiology. Spontaneous Closure of Atrial Septal Defects in Premature vs Full-Term Neonates
Pediatr Cardiol 21:129 134, 2000 DOI: 10.1007/s002469910020 Pediatric Cardiology Springer-Verlag New York Inc. 2000 Spontaneous Closure of Atrial Septal Defects in Premature vs Full-Term Neonates T. Riggs,
More informationClinical Policy Title: Inhaled nitric oxide
Clinical Policy Title: Inhaled nitric oxide Clinical Policy Number: 11.02.02 Effective Date: June 1 2014 Initial Review Date: February 19, 2014 Most Recent Review Date: May 17, 2017 Next Review Date: March
More informationSurfactant Administration
Approved by: Surfactant Administration Gail Cameron Senior Director Operations, Maternal, Neonatal & Child Health Programs Dr. Paul Byrne Medical Director, Neonatology Neonatal Policy & Procedures Manual
More informationMedical Coverage Policy
Medical Coverage Policy Subject: Inhaled Nitric Oxide Policy #: MED Current Effective Date: 11/10/14 Status: New Last Review Date: 11/10/14 Description/Scope Hypoxic respiratory failure may result from
More informationUPDATE IN HOSPITAL MEDICINE
UPDATE IN HOSPITAL MEDICINE FLORIDA CHAPTER ACP MEETING 2016 Himangi Kaushal, M.D., F.A.C.P. Program Director Memorial Healthcare System Internal Medicine Residency DISCLOSURES None OBJECTIVES Review some
More informationDepartment of Pediatrics, Shin Kong WHS Memorial Hospital, Taipei, Taiwan. 3
ORIGINAL ARTICLE The Use of Montelukast in Six Ventilator Dependent Infants Cheng I 1,2, Tsai Li-Yi 2, Chen Yi-Lin 2, Ho Shih-Ping 2, Mu Shu-Chi 2,3,4 1 Department of Pediatrics, Taitung Christian Hospital,
More informationUsing Nightingale to Identify Opportunities for Improvement
Using Nightingale to Identify Opportunities for Improvement Erika M. Edwards PhD, MPH Director of Data Systems and Analytics Vermont Oxford Network Research Assistant Professor Mathematics and Statistics
More informationMEDICAL POLICY I. POLICY POLICY TITLE POLICY NUMBER INHALED NITRIC OXIDE MP-4.021
Original Issue Date (Created): August 23, 2002 Most Recent Review Date (Revised): January 28, 2014 Effective Date: April 1, 2014 I. POLICY Inhaled nitric oxide may be considered medically necessary as
More informationVarious studies suggest that pulmonary inflammation
Early Postnatal Dexamethasone Therapy for the Prevention of Chronic Lung Disease in Preterm Infants With Respiratory Distress Syndrome: A Multicenter Clinical Trial Tsu F. Yeh, MD*; Yuh J. Lin, MD*; Wu
More informationSteroid in Paediatric Sepsis. Dr Pon Kah Min Hospital Pulau Pinang
Steroid in Paediatric Sepsis Dr Pon Kah Min Hospital Pulau Pinang Contents Importance of steroid in sepsis Literature Review for adult studies Literature Review for paediatric studies Conclusions. Rationale
More informationINTRAVENOUS FLUID THERAPY
INTRAVENOUS FLUID THERAPY PRINCIPLES Postnatal physiological weight loss is approximately 5 10% in first week of life Preterm neonates have more total body water and may lose 10 15% of their weight in
More informationINTRAVENOUS FLUIDS PRINCIPLES
INTRAVENOUS FLUIDS PRINCIPLES Postnatal physiological weight loss is approximately 5-10% Postnatal diuresis is delayed in Respiratory Distress Syndrome (RDS) Preterm babies have limited capacity to excrete
More informationVon Reuss and CPAP, Disclosures CPAP. Noninvasive respiratory therapieswhy bother? Noninvasive respiratory therapies- types
Noninvasive respiratory therapiesby a nose? NEO- The Conference for Neonatology February 21, 2014 Disclosures I have no relevant financial relationships to disclose or conflicts of interest to release.
More informationAdmission/Discharge Form for Infants Born in Please DO NOT mail or fax this form to the CPQCC Data Center. This form is for internal use ONLY.
Selection Criteria Admission/Discharge Form for Infants Born in 2016 To be eligible, you MUST answer YES to at least one of the possible criteria (A-C) A. 401 1500 grams o Yes B. GA range 22 0/7 31 6/7
More informationPostnatal growth failure Causes, consequences and prevention
Postnatal growth failure Causes, consequences and prevention Bielsko March 9, 2014 Ekhard E. Ziegler, M.D. Fomon Infant Nutrition Unit University of Iowa 1995; 26-29 weeks gestation NICHD Growth Observational
More informationLong-Term Effects of Inhaled Budesonide for Bronchopulmonary Dysplasia
The new england journal of medicine Original Article Long-Term Effects of Inhaled Budesonide for Bronchopulmonary Dysplasia Dirk Bassler, M.D., Eric S. Shinwell, M.D., Mikko Hallman, M.D., Ph.D., Pierre
More informationPulmonary administration of corticosteroids using lung surfactant at a delivering vehicle
Pulmonary administration of corticosteroids using lung surfactant at a delivering vehicle Yi Zuo, Asst. Prof. Department of Mech. Engineering College of Engineering University of Hawaii at Manoa Charles
More informationQuality Improvement Approaches to BPD. Jay P. Goldsmith, M.D. Tulane University New Orleans, Louisiana
Quality Improvement Approaches to BPD Jay P. Goldsmith, M.D. Tulane University New Orleans, Louisiana goldsmith.jay@gmail.com No conflicts of interest to declare There is nothing more dangerous to the
More informationAEROSURF Phase 2 Program Update Investor Conference Call
AEROSURF Phase 2 Program Update Investor Conference Call November 12, 2015 Forward Looking Statement To the extent that statements in this presentation are not strictly historical, including statements
More informationProphylactic nasal continuous positive airway pressure for preventing morbidity and mortality in very preterm infants(review)
Cochrane Database of Systematic Reviews Prophylactic nasal continuous positive airway pressure for preventing morbidity and mortality in very preterm infants (Review) SubramaniamP,HoJJ,DavisPG Subramaniam
More informationSubject: Inhaled Nitric Oxide (ino) for Neonatal Hypoxic Respiratory Failure. Original Effective Date: 10/4/12 10/30/13, 12/16/2015, 7/21/2016
Subject: Inhaled Nitric Oxide (ino) for Neonatal Hypoxic Respiratory Failure Original Effective Date: 10/4/12 Policy Number: MCP-121 Revision Date(s): 10/30/13, 12/16/2015, 7/21/2016 Review Date: 6/22/17
More informationabstract n engl j med 373;16 nejm.org October 15,
The new england journal of medicine established in 1812 October 15, 2015 vol. 373 no. 16 Early Inhaled Budesonide for the Prevention of Bronchopulmonary Dysplasia Dirk Bassler, M.D., Richard Plavka, M.D.,
More informationSWISS SOCIETY OF NEONATOLOGY. Spontaneous intestinal perforation or necrotizing enterocolitis?
SWISS SOCIETY OF NEONATOLOGY Spontaneous intestinal perforation or necrotizing enterocolitis? June 2004 2 Stocker M, Berger TM, Neonatal and Pediatric Intensive Care Unit, Children s Hospital of Lucerne,
More informationincreased incidence of cerebral
Arch Dis Child Fetal Neonatal Ed 2000;83:F177 F181 Kaplan Medical Center, Rechovot, Israel E S Shinwell S Mogilner Soroka Medical Center, Beersheva M Karplus Ha emek Medical Center, Afula D Reich Carmel
More informationNeonatal Outcomes in the Era of Periviability The Journey of Ontario s Tiniest Babies
Neonatal Outcomes in the Era of Periviability The Journey of Ontario s Tiniest Babies Paige Terrien, MD Director, Neonatal Follow Up Program University of Toronto Disclosure I do not have an affiliation
More informationPediatric Respiratory Disease: A Model for the Future of Emergency Medicine Research
Pediatric Respiratory Disease: A Model for the Future of Emergency Medicine Research Joseph J. Zorc, MD, MSCE Mark Fishman Professor, Department of Pediatrics Perelman School of Medicine, University of
More informationBubble CPAP for Respiratory Distress Syndrome in Preterm Infants
R E S E A R C H P A P E R Bubble CPAP for Respiratory Distress Syndrome in Preterm Infants JAGDISH KOTI*, SRINIVAS MURKI, PRAMOD GADDAM, ANUPAMA REDDY AND M DASARADHA RAMI REDDY From Fernandez Hospital
More informationInformed Consent for Standard of Care Research Interventions
Informed Consent for Standard of Care Research Interventions Jeffrey R Botkin, MD, MPH Associate Vice President for Research A case Two FDA approved drugs are commonly used for the treatment of hypertension.
More information